Alliance Global Partners Maintains Buy on Barinthus Biotherapeutics, Lowers Price Target to $9.5
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners maintains a Buy rating on Barinthus Biotherapeutics (NASDAQ:BRNS) but lowers the price target from $11 to $9.5.

August 13, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Alliance Global Partners maintains a Buy rating on Barinthus Biotherapeutics but lowers the price target from $11 to $9.5.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some concerns about near-term performance or market conditions. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100